British Journal of Haematology · 2021 · 52 citations · 24 references
MedicinePharmacologyPharmacotherapyClinical ImmunologyImmunopharmacologyImmunotherapyCytokine-based TherapyThrombocytopenia CareClinical RemissionImmune-mediated ThrombocytopeniaPhase Ii InvestigationRemission MeasurementThrombopoietin Receptor Agonists
Up to 30% immune thrombocytopenia (ITP) patients achieve a sustained remission off-treatment (SROT) after discontinuation of thrombopoietin receptor agonists (TPO-RAs). Factors predictive of response are lacking. Patients aged ≥18 years with newly diagnosed or persistent ITP were treated with eltrombopag for 24 weeks. Primary end-point was SROT: the proportion of responders that were able to taper and discontinue eltrombopag maintaining the response during a period of observation (PO) of six months. Secondary end-points included the association between some immunological parameters (TPO serum levels, cytokines and lymphocyte subsets) and response. Fifty-one patients were evaluable. Primary end-point was achieved in 13/51 (25%) treated patients and 13/34 (38%) patients who started the tapering. Baseline TPO levels were not associated with response at week 24 nor with SROT. Higher baseline levels of IL-10, IL-4, TNF-α and osteopontin were negative factors predictive of response (P = 0·001, 0·008, 0·02 and 0·03 respectively). This study confirms that SROT is feasible for a proportion of ITP patients treated with eltrombopag. Some biological parameters were predictive of response.
24
Paul A. Harris, Robert Taylor, Robert J. Thielke et al. · Journal of Biomedical Informatics · 2008 · 51.7K citations · Full text
Francesco Rodeghiero, Roberto Stasi, Terry Gernsheimer et al. · Blood · 2008 · 2.7K citations · Full text
Medicine, Hematology, Immunology +15
Science commentary: Th1 and Th2 responses: what are they?